These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26687594)

  • 1. 57th American Society of Hematology Annual Meeting.
    Smith LL
    Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
    [No Abstract]   [Full Text] [Related]  

  • 2. 58th American Society of Hematology Annual Meeting.
    Smith LL
    Lancet Haematol; 2017 Jan; 4(1):e13-e14. PubMed ID: 28041582
    [No Abstract]   [Full Text] [Related]  

  • 3. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
    Tallman M
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
    [No Abstract]   [Full Text] [Related]  

  • 4. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 5. The 51st annual meeting of the American Society of Hematology.
    Cunningham S; Muneer S; Ranganathan A; Shrader M
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):11-20. PubMed ID: 20223725
    [No Abstract]   [Full Text] [Related]  

  • 6. Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.
    Stone RM
    Expert Rev Hematol; 2013 Apr; 6(2):127-9. PubMed ID: 23547861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
    Glavey SV; Ghobrial IM
    Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing in on targeted therapy for acute myeloid leukaemia.
    The Lancet Haematology
    Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
    [No Abstract]   [Full Text] [Related]  

  • 9. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
    [No Abstract]   [Full Text] [Related]  

  • 10. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
    Loh KP; Christofyllakis K; Huang LW; Mims A
    J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
    [No Abstract]   [Full Text] [Related]  

  • 11. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
    Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
    Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
    [No Abstract]   [Full Text] [Related]  

  • 12. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
    Alrifai D; Pettengell R
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
    [No Abstract]   [Full Text] [Related]  

  • 14. Midostaurin Gets FDA Nod for AML.
    Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin + Chemo Ups AML Survival.
    Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora kinase inhibition as an anticancer strategy.
    Hilton JF; Shapiro GI
    J Clin Oncol; 2014 Jan; 32(1):57-9. PubMed ID: 24043748
    [No Abstract]   [Full Text] [Related]  

  • 18. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
    Lipka DB; Wagner MC; Dziadosz M; Fischer T
    Leukemia; 2016 Oct; 30(10):2090-2093. PubMed ID: 27137475
    [No Abstract]   [Full Text] [Related]  

  • 20. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.